Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Trial details
- Registry ID
- NCT04286607
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ARQ-151 Cream 0.3%
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisNCT04286607 | ARQT | Phase 3 | Completed | 2024-01-22Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |